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Abstract
Background: Accurate mRNA splicing depends on multiple regulatory signals encoded in the
transcribed RNA sequence. Many examples of mutations within human splice regulatory regions
that alter splicing qualitatively or quantitatively have been reported and allelic differences in mRNA
splicing are likely to be a common and important source of phenotypic diversity at the molecular
level, in addition to their contribution to genetic disease susceptibility. However, because the effect
of a mutation on the efficiency of mRNA splicing is often difficult to predict, many mutations that
cause disease through an effect on splicing are likely to remain undiscovered.
Results: We have combined a genome-wide scan for sequence polymorphisms likely to affect
mRNA splicing with analysis of publicly available Expressed Sequence Tag (EST) and exon array
data. The genome-wide scan uses published tools and identified 30,977 SNPs located within donor
and acceptor splice sites, branch points and exonic splicing enhancer elements. For 1,185 candidate
splicing polymorphisms the difference in splicing between alternative alleles was corroborated by
publicly available exon array data from 166 lymphoblastoid cell lines. We developed a novel
probabilistic method to infer allele-specific splicing from EST data. The method uses SNPs and
alternative mRNA isoforms mapped to EST sequences and models both regulated alternative
splicing as well as allele-specific splicing. We have also estimated heritability of splicing and report
that a greater proportion of genes show evidence of splicing heritability than show heritability of
overall gene expression level. Our results provide an extensive resource that can be used to assess
the possible effect on splicing of human polymorphisms in putative splice-regulatory sites.
Conclusion:  We report a set of genes showing evidence of allele-specific splicing from an
integrated analysis of genomic polymorphisms, EST data and exon array data, including several
examples for which there is experimental evidence of polymorphisms affecting splicing in the
literature. We also present a set of novel allele-specific splicing candidates and discuss the strengths
and weaknesses of alternative technologies for inferring the effect of sequence variants on mRNA
splicing.
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Background
One of the key tasks of the post-genome era is to deter-
mine the functional implications of genomic variants. The
development of high throughput genotyping technolo-
gies and the use of these technologies in large-scale studies
has enabled the identification of increasing numbers of
human loci that are associated with common genetic dis-
orders (e.g.[1]). However, the mechanisms through which
genetic variants at many disease-associated loci affect dis-
ease susceptibility remain to be determined. Mutations or
polymorphisms that affect mRNA splicing can have a pro-
found effect on the function of the spliced product, but
these effects are often difficult to predict from the primary
genomic sequence. The medical and biological signifi-
cance of such variants is evident from the large and rapidly
increasing volume of literature reporting examples of
aberrant mRNA splicing associated with human cancers
and genetic diseases [2,3]. Indeed, point mutations lead-
ing to aberrant splicing are thought to be among the most
important contributors to human genetic diseases [4].
Sequence variants found on the pre-mRNA can affect a
number of different, and in some cases imperfectly char-
acterized, cis-acting sequences that control splicing. Poly-
morphisms that occur at the highly conserved donor and
acceptor di-nucleotides are an obvious case in which we
expect an effect on splicing [5] and these genomic vari-
ants, when they occur close to verified exon boundaries,
tend be annotated in databases of sequence polymor-
phisms, such as dbSNP [6]. A much larger proportion of
variants are likely to occur at sites where the effect on
splicing is less obvious, for example at less conserved sites
close to intron/exon boundaries, close to the intronic
branch-point [7], or within intronic or exonic splicing
enhancer or suppressor sequences [8]. In some cases, such
sequence variants disrupt normal gene splicing, causing
aberrant splicing of either a proportion, or all of the tran-
scripts produced. However, if the gene is alternatively
spliced to begin with, then sequence variants that affect
sites that are involved in controlling isoform abundance
may be affected, causing allelic differences in the regula-
tion of alternative splicing, with potentially important
biological consequences [9].
The contribution of heritable variation to the observed
diversity of mRNA splice isoforms is well established [10-
12]. Using the ASAP database of alternatively spliced
mRNA isoforms [13] and transcribed SNPs, we previously
estimated that approximately 20% of alternatively spliced
genes show evidence of allele-specific splicing (either
complete allele-specific splicing, in which one allele gives
rise to one isoform and another results in the alternative
form, or partial allele-specific splicing in which different
alleles result in distinct relative isoform abundance [10]).
Earlier large-scale studies of alternative and allele-specific
splicing relied primarily on Expressed Sequence Tag (EST)
sequences. More recently, both exon-junction and exon
tiling arrays have been used for genome-wide studies of
alternative splicing [14,15]. The Affymetrix GeneChip
Human Exon 1.0 ST Array has probe-sets targeting
approximately 1.4 million known and predicted exons.
Alternatively spliced mRNA isoforms detected using the
Affymetrix exon array in cell lines genotyped as part of the
HapMap project [16], has given rise to opportunities for
high-throughput discovery of alleles that affect mRNA
splicing [11,12]. Though exon arrays are arguably a supe-
rior technology, with better exon coverage than ESTs [12],
they are also affected by a range of caveats that need to be
considered [17]. Integration of results from ESTs and
microarrays is likely to increase power to detect allele-spe-
cific splicing as both arrays and ESTs have different limita-
tions and advantages for the analysis of alternatively
spliced isoforms.
Though for the present it remains a distant goal, a com-
plete description of the effect of human sequence variants
on mRNA splicing would be a powerful resource for
understanding human genetic diseases and phenotypes.
One option for evaluating the potential effect of cis-acting
mutations on splicing is to use ab initio prediction algo-
rithms that make use of the availability of the complete
human genome sequence [18,19]. In several previous
studies, computational tools have been effective in help-
ing to shed light on the impact of a mutation on splicing
[9,20,21] and databases of mutations that may affect
splicing have been made available [22,23]. However,
because of the difficulty of predicting all splice regulatory
elements from genomic sequence and the even greater dif-
ficulty of determining accurately the effect of mutations in
these regions on splicing, genomic analysis of SNPs likely
to affect splicing needs to be complemented by expression
data that provides information about the splice isoforms
that are associated with the alternative alleles of a candi-
date SNP.
We have performed a genome-wide scan for Single Nucle-
otide Polymorphisms (SNPs) likely to influence splicing
efficiency in cis using publicly available tools (ESEfinder,
[19], MaxENTScan [18], and Branch Site Analyzer [24]).
We have tested predictions based on genomic sequences
using publicly available EST and exon array data. We
present a novel probabilistic method to infer allelic differ-
ences in mRNA splicing from EST data, and use recently
published Affymetrix exon array hybridisation data
derived from 166 lymphoblastoid cell lines [25] for which
genome-wide genotype data are available through the
HapMap project [16] to test for association between
mRNA isoforms and the genotype of putative cis-acting
splicing polymorphisms. We have also investigated theBMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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heritability of splicing and compared it to heritability of
transcript level expression using the exon array data.
Results
A genome-wide scan for polymorphisms in splice-
regulatory regions
We used published computational tools and identified
30,977 polymorphisms that occur within predicted or
known splicing regulatory sequences (srSNPs), including
donor sites, acceptor sites, branch points (BP) and exonic
splice enhancer (ESE) elements [see Additional file 1]. The
number of SNPs occurring in putative ESEs is much higher
than the number in the other cis elements (Table 1). This
is likely to be due, at least in part, to the high false positive
rate of ESE identification compared to the other splice reg-
ulatory elements that are identified using positional infor-
mation, rather than by matching to sequence patterns
alone. For each type of splice-regulatory element, publicly
available tools were used to score the sequences associ-
ated with alternative SNP alleles (see Methods) and score
differences for the identified polymorphisms are reported
as supplementary data. We used gene structure informa-
tion from Ensembl [26] as well as from ASAPII [27], to
identify srSNPs. This greatly increased our coverage, for
example, of the 9,201 polymorphisms identified in donor
and acceptor regions (including 17 in dual-specificity sites
[28]), 3,868 occurred within exon-intron or intron-exon
boundaries common to both databases while 2,759 were
unique to Ensembl and 2,574 were unique to ASAPII.
A maximum likelihood method to identify allele-specific 
splicing using EST data
We previously used linkage disequilibrium between SNPs
mapped to EST sequences and alternative splice isoforms
to identify allele-specific mRNA isoforms [10]. However,
because alternative splicing can be regulated in a tissue-
specific manner and because multiple ESTs from the same
gene can occur in a single cDNA library, we restricted our
previous analysis to just one EST per cDNA library per
alternative isoform pair. To make better use of the availa-
ble data we have now developed a probabilistic model
that can be applied to detect allele-specific splicing from
SNPs mapped to EST sequences (see Methods and an
illustration of the data for an example gene in Figure 1).
The possibility that the isoform is regulated in a tissue-
specific manner is modeled explicitly. For a given pair of
mutually exclusive mRNA isoforms, the proportions of
each isoform that occur across different cDNA libraries are
modeled using a beta distribution. An allelic effect on
splicing is inferred when a model that allows separate beta
distributions for two alternative alleles of a SNP (which
maps to both isoforms) provides a better fit to the data
than a model with a single distribution for both alleles.
We found 1,753 marker SNPs (i.e. SNPs in linkage dise-
quilibrium with a splicing event, which we refer to as
mSNPs), corresponding to 1,318 genes and 2,283 alterna-
tive splice junction pairs, for which the allele-specific
mRNA splicing model provided a better fit to the data
than the null model at the 5% significance level, using the
likelihood ratio test [see Additional file 2].
The distribution of the likelihood ratio test statistic is
asymptotically chi-squared for large sample sizes under
the null hypothesis. To test the validity of the test on the
observed data, for which the number of data points per
test was highly variable, we simulated data identical to the
observed data in terms of the numbers of ESTs mapping
to alternative alleles and splice isoforms but conforming
to the null hypothesis of no association between mRNA
isoform and allele. The cumulative distribution of the
likelihood ratio statistic on this simulated data was con-
sistently lower than the chi-squared distribution with one
degree of freedom (data not shown), which suggests that
the likelihood ratio test provides a conservative basis on
which to reject the null hypothesis. The distribution of p-
values from the simulated data was also not uniform
because of the sparseness of the data available for many of
the mSNP and splice junctions that were tested. This com-
plicates the application of standard false discovery rate
methods to account for multiple testing. Instead we com-
pared the observed and simulated distributions of the
likelihood ratio test statistic, which allowed us to estimate
the proportion of false discoveries at all levels of the test
statistic (Figure 2). There were 91 cases of association
between mSNPs and splice isoforms at the true positive
rate cut-off of 0.8, shown on the graph (corresponding to
approximately 73 true positives and 18 false positives; Fig-
Table 1: Summary of srSNPs with supporting evidence from EST and Exon array data.
Ciselement srSNPs EST evidence (α = 0.05) Exon array (FDR = 0.1) Exon array (Holm corrected α = 0.05)
Donor 1970 47 84 20
Acceptor 7248 156 217 22
Branch 2689 41 75 13
ESEs SC35 5910 44 257 26
SF2 8992 82 387 44
SRp40 7776 94 334 32
SRp55 5231 64 211 19BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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ure 2). These came from 54 distinct alternate splice junc-
tion pairs and 51 different genes.
Support for srSNPs and mSNPs from publicly-available 
exon array data
Exon array data generated by Huang et al. [25] from 166
lymphoblastoid cell lines using the Affymetrix Exon 1.0
ST array were downloaded from the GEO database [29],
and processed as described in Methods. The splicing index
(SI; [30]) was calculated for each probeset (including
high-confidence core probesets as well as probesets corre-
sponding to predicted exons), by dividing the probeset-
level expression estimate by the meta-probeset (or tran-
script) level expression estimate. The transcript-level
expression estimates were inferred using core probesets
only, to avoid inaccuracy caused by including spurious
probesets in the transcript-level expression estimate [12].
Genome-wide genotype data for almost four million SNPs
were available for the same cell lines through the HapMap
project [23]. For each putative srSNP and mSNP for which
genotype data were available we tested for an effect of gen-
otype on SI for each probeset in the region of the mSNP
or srSNP, treating the HapMap population from which
the sample was derived (Yoruban or Caucasian) as a cov-
ariate, and using a robust linear model and robust analysis
of variance (ANOVA), implemented in the Insightful
Robust Library of the R package [31,32]. In the case of
srSNPs, because it is often difficult to predict the impact of
the SNP on splicing, all probesets within 1 kb of the SNP
were tested. For the mSNPs we tested only probesets that
fell within the genomic boundaries defined by the alterna-
tive exon junctions of the putatively allele-specific splice
isoforms (i.e. probesets with genomic coordinates
between the minimum and maximum of the genomic
coordinates of the exon boundaries implicated in the
alternative splicing event). Similarly, to determine
whether an srSNP was supported by EST data, we tested
whether the srSNP fell within the genomic region defined
Data used to detect mSNPs Figure 1
Data used to detect mSNPs. Part of the genomic sequence of the OAS1 gene showing alternative acceptor site use at exon 
7. The putative causative SNP (rs10774671), which occurs at the G site of the canonical acceptor dinucleotide, and an mSNP 
(rs2660), which was used to infer allele-specific splicing from EST data, are shown. Splice isoforms and mSNP alleles observed 
in three of a total of 27 cDNA libraries with ESTs that mapped to this region are also depicted. For each library the data are 
summarized in a two-by-two contingency table, with each ESTs cross-classified according to mRNA isoform and SNP allele.BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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by the alternative exon junctions (including 3 bp of the
corresponding exons in the case of putative exonic splice
donor and acceptor mutations). Examples of srSNPs for
which there was strong evidence of an allelic effect on
splicing from the exon array data (Holm-corrected p-value
< 0.05) are shown in Figures 3 and 4. Similar diagrams are
available for a total of 1,185 putative srSNPs for which
there was a probeset SI significantly associated with geno-
type [see Additional file 3].
Among the classes of splicing regulatory regions analysed,
SNPs that occurred in donor sites were slightly more likely
to be confirmed by EST and/or exon array data (Table 1).
In addition to the srSNPs for which there is supporting
evidence from EST and/or exon array data a further 66
mSNPs were supported by exon array data, but no candi-
date srSNP was identified that could explain the allelic dif-
ference in splicing. Some of these may be false positive
mSNPs but for the remainder, the causative SNP may be
in an intronic splicing element (intronic splicing elements
were not included in the genome-wide scan for srSNPs) or
in, as yet, uncharacterized splicing regulatory elements.
The possibility also exists that some of the identified puta-
tive allele-specific isoforms are caused by mutations
located within trans regulators of splicing and that associ-
ation with nearby polymorphisms is a result of popula-
tion stratification rather than a direct cis-acting effect.
Cross-validation of EST and exon array results
Of the 54 distinct alternate exon junction pairs with evi-
dence of allele specific splicing from the EST data using a
false detection cut-off of 0.2 (see above), 15 could be
tested for allele-specific splicing using the exon array data
(in order to be tested the mSNP had to be among the SNPs
genotyped in the HapMap populations, a probe or probes
had to occur between the genomic coordinates spanned
by the alternative exon junction pair and the probe had to
be detectable above background in at least some of the
Analysis of simulated EST data Figure 2
Analysis of simulated EST data. Results of analysis of randomized EST data. The number of true positives and the true pos-
itive rate (equal to one minus the false discovery rate) as a function of the likelihood ratio test statistic were estimated from 
1000 randomizations of the matrices of counts of ESTs mapping to alternative SNP alleles and alternative splice isoforms. The 
solid line shows the number of true positives obtained when the true positive rate is 0.8 (i.e. at a false discovery rate of 0.2).BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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Allele-specific splicing evidence in the OAS1 based on exon array analysis Figure 3
Allele-specific splicing evidence in the OAS1 based on exon array analysis. Support for allele-specific acceptor site 
use in the OAS1 gene. (A) Genomic sequence of OAS1 showing the alternatively spliced exons. The boxed section is magnified 
and drawn to scale in the next panel. (B) Relationship between the genotypes of the SNP and splicing indices of nearby 
probesets, illustrating that there is likely to be a complex pattern of allele-specific splicing in this gene. Probesets in red are sig-
nificantly associated with the SNP genotype. The p-values for the association of these probesets to SNP genotypes are also 
included. Unfilled rectangles represent probesets that were not tested for an association with the genotype because they were 
not detected above background in a sufficient number of the cell lines, or were too distant from the SNP. (C) Histograms 
showing the splicing index distribution as a function of the genotype of a SNP, rs10774671, at the G nucleotide of the canonical 
splice acceptor site. (D) Association plot illustrating that rs10774671 is more strongly associated with a probeset between the 
SNP and an alternative acceptor site than any other SNP in the region for which genotype data were available.BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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Allele-specific splicing evidence in the GLO1 based on exon array analysis Figure 4
Allele-specific splicing evidence in the GLO1 based on exon array analysis. Support for allele-specific exon-skipping in 
the GLO1 gene. (A) Genomic sequence of the GLO1 gene showing the alternatively spliced exons. The boxed section is magni-
fied and drawn to scale in the next panel. (B) Illustration of the relationship between the genotypes of this SNP and splicing 
indices of nearby probesets, using the same conventions as in Figure 3. (C) Histograms showing the splicing index distribution 
as a function of the genotype of a SNP, rs2736654, predicted to affect an exonic splice enhancer site. (D) Association plot illus-
trating that rs2736654 is marginally more strongly associated with a probeset spanning exon 4 than any of the other SNPs in 
the region for which genotype data were available.BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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cell lines). Of these 15, 9 (60%) had at least one probe
between the genomic coordinates of the junction pair for
which the SI was significantly associated with the geno-
type of the mSNP (p < 0.05, with Bonferroni correction in
the case where multiple probes were tested for association
with a single mSNP). By comparison, for a random set of
10,000 alternatively spliced exon junction pairs from
ASAPII and nearby exonic SNPs that showed no associa-
tion with the mRNA isoform there were 252 (22%) asso-
ciations from 1,167 exon junctions that could be tested.
The proportion of allele-specific splicing candidates from
the EST data that could be confirmed using the exon array
data was significantly higher than for alternatively spliced
exon junctions with no evidence of allele-specificity from
ESTs (p = 0.002 using Fisher's Exact Test). This overlap of
allele-specific splicing candidates identified by very differ-
ent technologies, provides cross-validation for the candi-
dates identified using the two approaches.
Splicing index association plots
A significant association between the SI of a probeset and
an srSNP is insufficient to infer a causal relationship
between the srSNP and variation in SI. It is possible that
the putative srSNP is not causally related to the observed
difference in splicing and, instead, that it is in linkage dis-
equilibrium with a nearby SNP that was not predicted to
affect splicing (because of the imperfect understanding of
splicing regulation). We can begin to investigate this pos-
sibility by testing for an association between the SI and
genotype for all of the other nearby SNPs for which geno-
type data are available for the lymphoblastoid cell lines.
For each srSNP we tested for an association between SI
and genotype for all genotyped SNPs within 10 kb of the
srSNP. On average there were 25 such SNPs per srSNP. For
the majority (61.8%) of the srSNPs supported by the exon
array data (fdr < 0.1), the predicted srSNP showed the
most significant or joint most significant association
between SI and genotype for at least one of the probesets
tested. For the remainder, an alternative SNP, not neces-
sarily predicted to affect splicing, showed a more strongly
significant association. The mechanisms through which
these alternative SNPs may affect splicing require further
investigation. Examples of the association plots are shown
in Figures 3 and 4. Similar association plots for all of the
srSNPs supported by the exon array data are available
from http://mancala.cbio.uct.ac.za/splicing/ExonArray.
Analysis of allele-specific mRNA splicing candidates
For several of the examples of allele-specific splicing that
we identified we were able to find published research arti-
cles confirming the same event (Table 2). The mSNP
rs2660 (p = 0.0006; Figure 1), which we detected in the
2',5'-oligoadenylate synthetase 1 (OAS1) gene, for exam-
ple, has been shown experimentally to be in strong link-
age disequilibrium with the srSNP, rs10774671, which
occurs at the G of a canonical acceptor site [33]. Disrup-
tion of the canonical acceptor site in intron 6 of the OAS1
gene promotes the use of two cryptic acceptor sites. Using
the EST data we detected one of the cryptic acceptor sites,
located 98 bps from the wild type acceptor site (Figure 1).
This event was also detectable using the exon array data
(Figure 3).
There are also many cases of previously unpublished
splicing polymorphisms among our results, some of
which are likely to be functionally and medically impor-
tant. For example, the exon array data provide strong evi-
dence (robust ANOVA F statistic: 40.5; p = 9 × 10-11) for
an association between a probeset in exon 4 of the GLO1
gene, encoding an enzyme (glyoxalase I) that has been
reported to show lower activity in the brains of individu-
als affected by autism compared to control individuals
[34] and the genotype of a SNP in the same exon (C419A
or rs2736654; Figure 4). Reduction in enzyme activity has
been attributed to the direct effect of this non-synony-
mous SNP on the amino acid sequence of the protein. The
ancestral A allele has been reported to be significantly
associated with autism [34] and certain types of panic dis-
orders [35]. A larger scale study, however, has questioned
the association with autism, but has found that the A
Table 2: A subset of the previously reported allele-specific splice isoforms detected in this study
Gene Exon mSNP (p-value) mSNP (p-value from 
exon array data)
srSNP 
(exon-array p-value)
Cis-element References
CD45 Exon 4 rs12129883 (0.020551) --- --- ESS [54]
COL5A1 Exon 65 rs13946 (0.046) --- --- Acceptor site [55]
ETV4 Exon 3 rs3765174 (0.014) --- --- NAGNAG acceptor [39]
GABRR1 Exon 2 rs12200969 (0.034) --- rs4590242-NA- NAGNAG acceptor [39]
ITPA Exon 2 and Exon 3 rs13830 (0.030) 0.0042 --- Exonic splicing silencer 
element in exon 2
[56]
MUC1 Exon 2 rs4072037 (0.0011) --- --- Acceptor site [57]
OAS1 Exon 7 rs2660 (0.00063) 2.78 × 10-15 rs10774671 (< 10-16) Acceptor [33]
PMM2 Exon 5 rs2072688 (0.0027) --- --- ESE [44]
RBM23 Exon 6 rs1951119 (1.0 × 10-6) 0.0140 rs2295682 (0.0027) SRp40* [11]
UROD Exon 4 rs1804886 (0.0027) --- --- --- [58]
* Hull et al. [11] did not report that the SNP, rs2295982, disrupts an ESEBMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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allele may have a protective effect in the siblings of indi-
viduals with autism [36]. This non-synonymous SNP
occurs in a predicted exon splice enhancer site (the
genomic scan for srSNPs predicts that this site acts as an
ESE for both SF2 and SRp55 and the A and C alleles have
scores 0.44 and 2.96, respectively, for SF2 and 1.39 and
3.53, respectively for SRp55). EST evidence from ASAPII
suggests that two exons are skipped [27]. Skipping of
these exons is likely to have a much greater impact on the
protein function than the replacement of alanine by
glutamine at a single site within one of the exons. While
the role of GLO1 in neurological disorders remains con-
troversial [37], Sacco et al. [36], highlight the need for fur-
ther investigation of the functional impact of the C419A.
Our results suggest that the polymorphism is very likely to
impact on splicing. This could have a significant impact
on glyoxalase I activity and be the mechanism underlying
the disease association.
Heritability of splicing
We assessed the heritability of splicing index by estimat-
ing the slope of the correlation of child SI with the mean
of parent SI values for 46 two-parent and child trios, for
which exon array data were available for the complete
trio. Using only core probesets and meta-probesets, the
mean of the slope as well as the mean of Pearson's corre-
lation coefficient were positive (0.093 and 0.084, respec-
tively) and significantly different from zero (p < 10-16 in
each case), but significantly less than the mean values
obtained when we performed the same regression using
estimated transcript-level (i.e. meta-probeset) expression
values, for which the corresponding values were 0.163
and 0.146. We estimated the proportion of SI values that
do not conform to the null hypothesis (which assumes no
correlation between mean parent SI and child SI) using
the method described by Storey and Tibshirani [38]. This
proportion was 15% for splicing index, rising to 35% for
transcript-level expression estimates. This suggests that
probeset splicing index is, on average, somewhat less her-
itable than whole transcript expression. However, because
probeset expression levels are estimated from much
smaller numbers of probes than transcript level expres-
sion, probeset expression level estimates are likely to be
noisier and this may contribute to their apparently lower
heritability. It is also important to note that there were
approximately 13 probesets per core meta-probeset. At the
1% significance level, 4.8% of probesets were correlated
between child and the mean of the parent values. This fig-
ure was 7.7% for meta-probeset expression level esti-
mates, but 12.3% of genes had at least one probeset with
a significantly correlated SI value (applying Bonferroni
correction for multiple probesets per meta-probeset).
Therefore, heritability of the relative expression of parts of
transcripts appears to be common, even more so than her-
itability of overall gene expression level.
Discussion
Large-scale discovery of genomic variants that affect splic-
ing has the capacity to accelerate the association of dis-
eases to causative genomic variants. However, because it is
difficult, and in many cases currently not possible, to
determine the effect of a genomic variant on splicing or on
the regulation of alternative splice isoforms from genomic
sequence data alone, this remains a challenging task and
requires the integration of information from different
data types. At present, no single source of data can provide
information about all forms of splice variants and each
source of data has advantages as well as disadvantages.
The publicly available exon array data that we have used
here represents an extremely extensive dataset on isoform
abundance in human lymphoblastoid cell lines that can
be correlated with the genotype of the cell line. However,
this data provides no information on transcripts that are
not expressed in lymphoblastoid cell lines, or on splicing
mutations that affect relative isoform abundance in only
a subset of expression contexts. Furthermore, depending
on the exact location of probesets in a given gene, many
of the transcript isoforms that occur, particularly those
that affect donor or acceptor site but do not cause exon
skipping or inclusion, are undetectable using exon arrays.
When alternative isoforms are distinguishable using the
exon arrays, they still provide little information on the
nature of the isoforms, and this may need to be inferred
either by integrating information from other sources or
experimentally.
EST sequences provide information on the structure of
alternative isoforms and include data from different gene
expression contexts, but this information is highly biased
towards ends of genes and is sparse, for all but the most
highly expressed genes. The simulations provide ample
evidence for frequent allele-specific splicing but also illus-
trate that there is not enough data to confirm most cases,
especially when the effect of a very large number of statis-
tical tests is considered. There were several published
examples in the current study of genes known to be
spliced in an allele-specific manner, but for which the
allele-specific splicing model fits the data no better than
the null model. However, although most cases of allele-
specific splicing will not be detectable using EST
sequences alone, ESTs can often be used to elucidate the
nature of the allele-specific splicing events detected
because ESTs provide information on the actual tran-
scripts that occur. We compared the length differences
between alternatively spliced isoform pairs with and with-
out evidence of allele specific splicing from the EST anal-
ysis. Across all classes of alternative splicing considered
the length differences between isoform pairs were smaller
for pairs with evidence of allele-specific splicing. There
was also evidence of a trend towards a greater likelihoodBMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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of frame preservation among the isoforms with evidence
of allele specificity [see Additional file 4].
GLO1 provides an example of a gene with a mutation that
is likely to affect splicing, but although there was good
coverage of this gene in the EST databases, the allele-spe-
cific splicing event was not detectable from the EST data.
Because the putative causal SNP is on the skipped exon it
is only observed when the constitutive isoform occurs and
therefore cannot be tested for association with the skip-
ping event using the EST data. Furthermore, there is only
one EST that captures the exon skipping event, denoted by
junction 334716 in ASAPII. There are also several cases of
known splicing polymorphisms that could be detected
from ESTs but not from the exon array data (Table 2). The
gamma-aminobutyric acid (GABA) receptor, rho 1, gene
(GABRR1), for example, was previously shown to have a
SNP (rs4590242), located in the acceptor site that pro-
motes use of an alternate NAGNAG acceptor [39]. We
detected this srSNP in the genomic data and EST data pro-
vided evidence of its effect on splicing with an mSNP
rs12200969, (p-value = 0.03). However, due to the lack of
a probe that coincides exactly with the end of the exon, the
exon arrays were unable to detect this subtle alternative
splicing event.
The probability of linkage disequilibrium of an srSNP and
mSNP decreases with the distance that separates them.
This limitation is highlighted by the failure to associate
several transcribed SNPs (rs3093906, rs3093905,
rs3093921, rs3093925, rs3093926, and rs3093927),
located >5000 bp away from a putative allele-specific
splicing event in the Ribonuclease P RNA component H1
gene (PARP-2). The ASAPII database contains the two
alternate donor sites at this junction that are 39 bp apart
and are supported by a total of 28 expressed transcripts,
and two PARP-2 protein isoforms differing by 13 amino
acids have been deposited in the SWISSPROT database
[40]. We detected an srSNP (rs2297616) located at posi-
tion 4 of the corresponding splice donor site and the
exon-array data provide strong evidence for an association
between the splicing index of a probeset that overlaps the
39 bp region between the alternative donor sites and the
genotype of this SNP (p-value = 2 × 10-5).
In previous work we used a heuristic method to find asso-
ciations between SNPs mapped to ESTs and alternatively
spliced isoforms in order to detect candidate allele-spe-
cific isoforms and to quantify the proportion of alterna-
tively spliced genes that are spliced allele-specifically [10].
However, such associations can also occur because of nor-
mal regulation of alternative splicing. For example, con-
sider an alternatively spliced gene for which ESTs occur in
just two of the cDNA libraries in dbEST. Assuming that
these libraries were constructed from the tissues of single
individuals, it is possible that these individuals have dif-
ferent genotypes for an exonic SNP in the gene. If the alter-
native isoforms of the gene happen to be regulated in a
tissue specific way and if the cDNA libraries are derived
from different tissues then this could result in an associa-
tion between the alleles of the SNP and the mRNA iso-
forms. This association can be highly significant if there
are many ESTs of the gene in the two cDNA libraries in
which it occurs. To circumvent this problem in our previ-
ous work, we took a maximum of two ESTs per cDNA
library (one for each allele of the SNP from heterozygous
libraries and just one from homozygous libraries). This
caused a substantial loss of data and reduction in power
to detect and quantify allele-specific mRNA splicing. In
the present work we explicitly model the regulation of
alternative splicing and make much better use of the avail-
able data.
Our results and previous reports [10,12] suggest that pol-
ymorphisms that affect splicing are common. This has
important implications, not only for discovering the
molecular bases of genetic diseases, but also for the study
of alternative splicing. A gene cannot be confirmed to be
alternatively spliced unless multiple isoforms are
observed from the same allele. Until then the possibility
remains that the alternative isoforms observed are poly-
morphic variants rather than alternatively spliced.
Although we have found ample evidence for allelic differ-
ences in splicing, isoforms that result entirely from
sequence variants might be less common. In the set of
examples we report here, there is a relatively small propor-
tion of cases in which the data suggest that the SI might be
zero for some variants. Allele-specific splicing may be par-
ticularly important in the context of investigations of the
regulation of alternative splicing [41,42]. Such investiga-
tions should ensure that multiple samples from the same
tissue source are not treated as independent. This was an
issue, in particular with early investigations of regulated
splicing using EST sequences, in which multiple samples
from the same cDNA library were used [42].
Regulation of splicing is incompletely characterized and
additional cis elements that regulate splicing are still being
discovered [43]. A limitation of the current study is that
the srSNP candidates are restricted to a subset of well char-
acterized cis-acting splice regulatory elements (donor and
acceptor sites, polypyrimidine tract, branch points, and
some exonic splicing elements). The phosphomanno-
mutase 2 gene (PMM2), for example, which has allele-
specific skipping of exon 5 due to a SNP that disrupts an
ESE composed of (GAR)n repeats [44], where R is a
purine, was detected using the EST data (p = 0.003); how-
ever, we could not identify an srSNP because the disrupted
ESE is not detected by ESEfinder. Polymorphisms not
found in cis-regulatory regions can also result in apparentBMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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allele-specific splicing if they introduce premature termi-
nation codons (PTC) [45] and cause differential non-
sense-mediated decay of alternative alleles. Such SNPs are
not included in our srSNP database. We have also
restricted our analysis to single nucleotide polymor-
phisms but allele-specific splicing could be due in many
cases to other types of polymorphisms such as insertions
and deletions [46].
In the majority of the examples of allele-specific splicing
we have detected, the difference in splicing is quantitative
rather than qualitative. This can occur for a gene that is
alternatively spliced, but for which a polymorphism exists
that affects the proportions of alternative isoforms pro-
duced. In some cases, particularly for common polymor-
phisms, the size of the effect on SI can be relatively small,
but still highly significant because of the relatively large
number of individuals in each genotype group. In other
cases, e.g., the alternative isoforms of the OAS1  gene
shown in Figure 3, the SI associated with one genotype
may be much greater than for the other genotypes. In gen-
eral, the size of an effect on SI sufficient for an effect on
phenotype is likely to vary substantially from transcript to
transcript. Consistent with what has been observed previ-
ously for cis-acting polymorphisms with a quantitative
effect on splicing [9], for the majority of the probesets for
which SI was significantly associated with SNP genotype,
the SI value of the heterozygote was intermediate to the SI
of the two homozygotes. In 904 (69%) of 1,318 associa-
tions (corresponding to 1,083 different srSNPs) for which
heterozygote and both homozygote cell-lines for the SNP
were available, the SI of the heterozygote had an interme-
diate value. This was the case for all of the 148 stronger
associations (that remained significant using a family-
wise error rate of 0.05).
Loci that affect splicing might be termed splicing quanti-
tative trait loci (sQTLs), by analogy with expression quan-
titative trait loci (eQTLs) that have become the subject of
significant interest [47]. Although the heritability of indi-
vidual SI values is, on average smaller than the heritability
of overall transcript expression level, our results suggest
that a greater proportion of genes show heritable splicing
of at least one region of the transcript, than heritability of
overall gene expression level. In this study we have
attempted to identify only cis-acting sQTLs. Trans-acting
sQTLs are also likely to exist, particularly at genes that are
involved in regulating alternative splicing, but the ratio of
trans to cis acting variants may be much smaller for sQTLs
than for eQTLs, because of the relatively more complex
regulation of transcription initiation compared to splic-
ing. We have taken a candidate SNP approach to detecting
splicing polymorphisms. With the availability of whole-
genome exon array data it is also possible to adopt a less
directed approach analogous to methods that have been
used previously to detect expression quantitative trait loci
[47]. Each probeset could be tested for association with
every SNP that overlaps the transcripts to which it
belongs. However, because of the multiplicity of
probesets per gene this would result in a very large
number of tests and would be likely to yield a much larger
set of candidates, but potentially a set with lower specifi-
city and for which interpretation is more difficult.
Although we could identify a large number of candidate
splicing polymorphisms by combining genomic, EST and
exon array data, many of which were strongly associated
with splicing, confirmation of causal relationships
between human sequence variants will require experi-
ment, probably involving mutagenesis so that relative iso-
form abundance can be compared between alternative
alleles against an identical genetic background.
Conclusion
We have carried out a genome-wide survey of human pol-
ymorphisms that are likely to affect mRNA splicing. We
developed a maximum likelihood approach to test for evi-
dence of allele-specific splicing from EST data. This was
complemented by an analysis of exon array data in the
public domain, generated from cell lines that were geno-
typed as part of the HapMap project. For each of the puta-
tive splicing polymorphisms identified in the genome-
wide scan, we tested for an association between splicing
index and SNP genotype and corroborated 1,185 exam-
ples at a false discovery rate cut-off of 0.1. We discuss
advantages and disadvantages of alternative high-
throughput methods to detect allele-specific splicing and
report that a higher proportion of transcripts show evi-
dence of heritability of mRNA splicing of at least some
part of the transcript, than show evidence of gene expres-
sion heritability at the whole transcript level. Our results
underscore the importance of mutations that affect splic-
ing for understanding human phenotypes and genetic dis-
eases and provide a resource that can be used to help
assess the effects of human polymorphisms on mRNA
splicing.
Methods
Identification of srSNPs
We downloaded known transcripts, chromosomal
genomic data and SNP and exon tables from Ensembl ver-
sion 36 [26], which is based on NCBI Genome build 35.
Genes and SNPs that mapped to multiple locations on the
genome were discarded. Introns were inferred from the
exon genomic coordinates obtained from Ensembl. SNP
positions relative to the Ensembl exons and introns were
identified via genomic coordinates. SNP positions relative
to exon/intron junctions were also determined for iso-
forms obtained from the ASAPII database.BMC Genomics 2008, 9:265 http://www.biomedcentral.com/1471-2164/9/265
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Published tools for detecting splicing regulatory elements
were either requested from authors or downloaded from
their respective sites. We extracted 9 nucleotides from the
donor splice sites and 23 nucleotides from the acceptor
splice sites as required by the maximum entropy algo-
rithm of Yeo and Burge, 2004 [18]. Scores for each pair of
alternate alleles were then calculated [18]. We also identi-
fied an inflated frequency of SNPs at the G base of the
canonical AG acceptor site which has been previously
identified as a sequencing artifact [48]. We therefore
restricted our analysis to validated SNPs using the infor-
mation from dbSNP125 in the Ensembl database.
The ESEfinder tool [19] is designed to predict four ESEs:
SC35, ASF2, SRp55, and SRp40. ESEfinder uses a position
specific weight matrix. An ESE is considered to have a pre-
defined length, m, and a recommended minimum score S.
For each SNP we extracted m-1 nucleotides up- and down-
stream of the SNP. We then calculated the ESE scores for
each of the contiguous length m  subsequences of this
sequence. The highest score for each SNP allele was
retained if at least one of the scores was above S and the
other below S. Although some strong ESEs can influence
splicing at a distance of several kilobases [49], functional
ESEs are most abundant in close proximity to splice junc-
tions of internal exons [50]. We therefore restricted our
analysis to ESEs located within 200 bps of exon-intron
junctions of internal exons. Branch point scores for pairs
of alternate SNP alleles were computed using Perl scripts
provided by Kol et al., 2005 [24].
Identification of mSNPs
We downloaded pre-computed EST and SNP genomic
locations from the UCSC Genome Browser [51], which is
based on NCBI genome assembly 36. ESTs and SNPs that
mapped multiple times onto the genomic sequence and
ESTs for which less than 90% of the sequence mapped to
the genome were discarded. We used SNP and EST
genomic coordinates to identify the SNP allele corre-
sponding to each EST overlapping the SNP position.
ASAPII [27], a database of alternatively spliced gene clus-
ters, was downloaded on 9/11/2006. This data included
gene and exon genomic locations based on NCBI genome
assembly 35 as well as alternative mRNA isoforms (repre-
sented by conflicting exon junction pairs) mapped to
ESTs.
Models of regulated and allele-specific splicing
For a given allele, A, of an alternatively spliced gene with
alternative splice isoforms S1 and S2, let x represent the
proportion of isoform S1 produced from allele A in a
cDNA library. We assume that x is constant for a given
allele and library, but may vary across alleles and/or
libraries. The purpose of the model is to determine, using
data from several libraries (in which alternative transcript
isoforms may be differentially regulated and have differ-
ent relative expression levels), whether x shows significant
variation across alleles.
Consider cDNA library i with N transcripts from allele A,
of which we observe ai ESTs that map to S1 and bi = N-ai
ESTs that map to S2. Because ai is binomially distributed
with binomial parameter x, we use the beta distribution
(conjugate to the binomial) to describe the probability
density of x. We share this distribution across all libraries
but not necessarily across the two alleles. Thus the values
of x  for separate libraries are modeled as independent
draws from the distribution f(x, αA, βA) for allele A and f(x,
αB, βB) for allele B, where f(x, α, β) is the beta function
with parameters α and β.
The likelihood of the data from allele A observed in
library i can now be expressed as
The likelihood of the data observed in all cDNA libraries
is a product over terms such as this, and the α and β
parameters can be estimated by optimizing the likelihood
for the combined data set.
An analytical solution to the integral of equation 1 exists,
resulting in the following expression for the likelihood of
the complete data for a pair of alternate isoforms and SNP
alleles:
where ai, bi are the numbers of ESTs in cDNA library i that
map to allele A and splice junctions S1 and S2 respectively
and ci, di are the corresponding EST counts for allele B. The
maximum likelihood parameter estimates were obtained
by optimizing the likelihood using Powell's method [52].
For the null model, we impose the restriction that αA = αB
and βA = βB, such that both alleles are considered to be
sampled from the same distribution (no allele-specific
effect). To model allele-specific splicing (the alternative
model), we allow αA ≠ αB and estimate separate beta dis-
tributions for the alternate alleles of a SNP (we keep the
constraint  βA =  βB because we found that this model
already has sufficient freedom to model the desired effect
and adding another degree of freedom was unnecessary).
If the null model can be rejected in favour of the alterna-
tive model (using the likelihood ratio test) we conclude
that there is evidence of allele-specific splicing.
LD x x fx d x iAA
ab
AA
ii |, ( ) ( ,,) αβ αβ () =− ∫ 1
0
1
(1)
LD AA aiA biA BB ciB
AABB |,,, αβαβ
αβ α β αβ α () =
+ () + () + () + () + () ΓΓ Γ ΓΓ Γ d diB
AA ai biAA B B ci diBB i
+ ()
() () ++ + () () () ++ + () ∏
β
αβ α βαβ α β ΓΓΓ ΓΓΓ
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Simulations
We constructed 1000 random replicates of the EST data
such that, for every SNP, the number of libraries derived
from each genotype of the SNP was identical to the real
data. Each library in the simulated data was assigned a
genotype, with a probability proportional to the number
of libraries of that genotype in the real data (this propor-
tion was adjusted as each simulated library was assigned a
genotype). For each library, the total numbers of ESTs
derived from each isoform was constrained to be the same
as in the real data. For heterozygous libraries ESTs were
assigned to alternative SNP alleles with equal probability.
Analysis of Affymetrix exon arrays
Whole genome exon data generated using the Affymetrix
Human Exon 1.0 ST array by Huang et al. [25] were
obtained from the Gene Expression Omnibus [29]. These
data were generated from 166 cell lines for which
genome-wide genotype data are available through the
HapMap project [16]. All probes that overlapped with
SNPs from dbSNP were removed because these may affect
hybridization and cause artifactual association [12]. The
exon array data was processed using the Affymetrix Power
Tools [53]. For all probesets we estimated expression level
in each cell-line using the Plier Sketch algorithm and esti-
mated detection above background probabilities using
DABG [53]. For the meta-probeset (transcript) level
expression we used only the high confidence (or 'core')
probesets from the array to avoid inaccuracy caused by the
inclusion of computationally predicted probesets [12].
For each probeset that mapped to a meta-probeset, the
splicing index (SI) was calculated by dividing the probeset
expression estimate by the estimate of the transcript-level
expression in each cell line. For non-core probesets that
mapped to core as well as non-core meta-probesets the
core meta-probeset expression estimate was used.
For each srSNP we used a robust linear model to test for
an association between the SI of all probes within 1 kb of
the probe and SNP genotype, using only unrelated indi-
viduals (i.e parents from the parent-child trios) and treat-
ing HapMap population as a covariate. We used Holm
correction (with significance level 0.05) to control the
family-wise error rate and establish a high-confidence or
conservative set of probes with allele-specific SI. A false
detection rate correction (also with cut-off set to 0.05) was
also used to generate a larger set of events that includes a
small proportion of false positive inferences. All statistical
analyses were performed using the R statistical computing
environment [31,32].
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